Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

MRSN

Mersana Therapeutics Inc

Apr 26 • 04:00PM ET

2.94

Dollar change +0.09
Percentage change 3.16	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF VTWO IWO IWN PTH LABU IWC VFMO

Index	RUT	P/E	-	EPS (ttm)	-1.50	Insider Own	24.18%	Shs Outstand	120.71M	Perf Week	-9.54%
Market Cap	356.62M	Forward P/E	-	EPS next Y	-0.72	Insider Trans	-0.23%	Shs Float	91.97M	Perf Month	-34.52%
Income	-171.67M	PEG	-	EPS next Q	-0.18	Inst Own	71.11%	Short Float	11.50%	Perf Quarter	-8.70%
Sales	36.85M	P/S	9.68	EPS this Y	55.50%	Inst Trans	4.10%	Short Ratio	4.77	Perf Half Y	164.86%
Book/sh	0.31	P/B	9.62	EPS next Y	-9.63%	ROA	-61.27%	Short Interest	10.58M	Perf Year	-24.42%
Cash/sh	1.72	P/C	1.71	EPS next 5Y	-	ROE	-266.24%	52W Range	0.80 - 9.62	Perf YTD	26.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.93%	ROI	-263.08%	52W High	-69.44%	Beta	1.61
Dividend TTM	-	Quick Ratio	3.36	Sales past 5Y	12371.94%	Gross Margin	95.88%	52W Low	266.86%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	3.36	EPS Y/Y TTM	31.64%	Oper. Margin	-463.86%	RSI (14)	26.46	Volatility	8.50% 7.28%
Employees	123	Debt/Eq	0.92	Sales Y/Y TTM	38.65%	Profit Margin	-465.80%	Recom	1.44	Target Price	6.50
Option/Short	Yes / Yes	LT Debt/Eq	0.77	EPS Q/Q	63.57%	Payout	-	Rel Volume	0.39	Prev Close	2.85
Sales Surprise	-27.40%	EPS Surprise	0.12%	Sales Q/Q	-27.14%	Earnings	Feb 28 BMO	Avg Volume	2.22M	Price	2.94
SMA20	-21.96%	SMA50	-33.02%	SMA200	14.63%	Trades		Volume	858,285	Change	3.16%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral	$5
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform	$2 → $7
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy	$7
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy	$6
Dec-04-23	Upgrade	Citigroup	Neutral → Buy	$1 → $5
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral	$7 → $1
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral	$11 → $5
Jun-15-23	Initiated	Guggenheim	Buy	$14
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight	$10
Jan-20-23	Initiated	Citigroup	Buy	$12
Nov-21-22	Initiated	Truist	Buy	$12
Oct-15-21	Resumed	BTIG Research	Buy	$32
Aug-30-21	Initiated	H.C. Wainwright	Buy	$28
Mar-31-21	Initiated	Credit Suisse	Neutral	$18

Show Previous Ratings

Apr-04-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-29-24 08:41AM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.16%
Feb-28-24 09:49PM	Q4 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.58%
08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:35AM	Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Loading…
07:00AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 08:01AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.17%
Feb-21-24 08:00AM	Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024 (GlobeNewswire)
Feb-20-24 10:00AM	Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-01-24 08:00AM	Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +6.96%
Jan-05-24 08:01AM	Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-23 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15%
Nov-08-23 02:42PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:13AM	Q3 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:10AM	Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Loading…
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 04:30PM	Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023 (GlobeNewswire) +7.21%
08:00AM	Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056 (GlobeNewswire)
Sep-07-23 06:30AM	The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure (American City Business Journals)
Sep-06-23 07:00AM	Mersana Therapeutics Announces Changes in Leadership (GlobeNewswire) +7.89%
Aug-18-23 09:35AM	After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN) (Zacks)
Aug-16-23 09:35AM	Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround (Zacks) -6.35%
Aug-08-23 09:40AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Mersana Therapeutics Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.24%
Jul-28-23 10:13AM	Block upgraded, Southwest downgraded: Wall Street's top analyst calls (The Fly) +17.76%
03:14AM	4 big analyst cuts: Snap slashed to Hold, Southwest gets several downgrades (Investing.com)
Jul-27-23 09:34PM	EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc (GuruFocus.com) -72.63%
01:44PM	Mersana slashes half its staff, loses $400M in value after trial failure (American City Business Journals)
07:06AM	Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization (GlobeNewswire)
09:45AM	Loading…
Jul-13-23 09:45AM	15 Best Penny Stocks To Buy Now (Insider Monkey)
Jul-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-16-23 10:43AM	Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold (Zacks) -10.80%
02:26AM	5 big analyst cuts: SoFi Technologies slashed with 3 downgrades, shares plunge (Investing.com)
Jun-15-23 09:32AM	Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser (Motley Fool) -59.27%
07:36AM	US FDA puts Mersana Therapeutics's ovarian cancer study on hold (Reuters)
07:30AM	Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials (GlobeNewswire)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +5.45%
Jun-02-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-23 09:06AM	Those who invested in Mersana Therapeutics (NASDAQ:MRSN) a year ago are up 127% (Simply Wall St.)
May-24-23 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-23 08:35AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.82%
07:00AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.00%
May-03-23 08:00AM	Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire) +46.12%
May-02-23 08:00AM	Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023 (GlobeNewswire) -7.01%
Apr-26-23 04:05PM	Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-17-23 11:07AM	Getting In Cheap On Mersana Therapeutics, Inc. (NASDAQ:MRSN) Is Unlikely (Simply Wall St.) +5.54%
Apr-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-05-23 02:00PM	J.P. Morgan Suggests 2 Stocks to Buy, Including One With 140% Upside Potential (TipRanks)
Mar-16-23 11:20AM	Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More (Zacks) +6.37%
Mar-13-23 02:00PM	FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death (Benzinga)
07:54AM	UPDATE 1-U.S. FDA places Mersana's cancer drug trial on hold following death (Reuters)
07:30AM	Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial (GlobeNewswire)
Mar-10-23 07:10PM	Mersana Therapeutics Provides Statement About SVB (GlobeNewswire) -12.00%
Mar-03-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-02-23 08:55PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 05:24AM	Mersana Therapeutics Full Year 2022 Earnings: US$2.18 loss per share (vs US$2.41 loss in FY 2021) (Simply Wall St.)
Feb-28-23 11:51PM	Q4 2022 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.60%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-21-23 08:00AM	Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023 (GlobeNewswire)
Feb-03-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-23 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-01-23 08:00AM	Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer (GlobeNewswire)
Jan-25-23 08:00AM	Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors (GlobeNewswire)
Jan-20-23 03:16PM	With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics (Benzinga) +9.97%
Jan-16-23 02:18AM	Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones (GlobeNewswire)
Dec-31-22 07:42AM	Estimating The Fair Value Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) (Simply Wall St.)
Dec-23-22 12:46PM	Merck KGaA inks deal worth up to $830M with Cambridge cancer biotech (American City Business Journals)
10:08AM	Mersana Inks Cancer Therapy Development Deal With Merck Germany (Benzinga)
Dec-22-22 04:08PM	Mersana signs deal with Merck KGaA for cancer therapy development (Reuters)
04:05PM	Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates (GlobeNewswire)
Dec-14-22 08:00AM	European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer (GlobeNewswire)
Dec-02-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.09%
Nov-08-22 08:00AM	Mersana Therapeutics to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-22 08:25AM	Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -11.94%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-22 08:00AM	Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022 (GlobeNewswire) +9.47%
Oct-30-22 10:13AM	Investing in Mersana Therapeutics (NASDAQ:MRSN) three years ago would have delivered you a 284% gain (Simply Wall St.)
Oct-17-22 09:40AM	Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year? (Zacks) +8.51%
Oct-06-22 04:05PM	Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer (GlobeNewswire)
Oct-04-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.44%
Sep-30-22 08:02AM	Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies (GlobeNewswire) +5.30%
Sep-12-22 08:00AM	Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer (GlobeNewswire)
Sep-06-22 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-02-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-22 10:17AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Aug-16-22 09:55AM	Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) -6.23%
08:00AM	Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers (GlobeNewswire)
Aug-12-22 06:05AM	The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals (Zacks)
Aug-11-22 11:25AM	Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates (Zacks)
Aug-09-22 06:58AM	Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy (Benzinga) +33.33%
Aug-08-22 05:15PM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:04PM	Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results (GlobeNewswire)
04:02PM	Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2 (GlobeNewswire)

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Protopapas Anna	Director	Jan 16 '24	Sale	2.71	29,399	79,671	125,153	Jan 17 05:21 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 16 '24	Sale	2.71	10,409	28,208	199,329	Jan 17 05:19 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 16 '24	Sale	2.71	9,327	25,276	54,511	Jan 17 05:18 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 16 '24	Sale	2.71	5,025	13,618	23,328	Jan 17 05:20 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 16 '24	Sale	2.71	4,381	11,873	27,403	Jan 17 05:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 16 '24	Sale	2.71	3,431	9,298	14,052	Jan 17 05:16 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 16 '24	Sale	2.71	3,357	9,097	17,966	Jan 17 05:21 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 15 '24	Option Exercise	0.00	15,208	0	209,738	Jan 17 05:19 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 15 '24	Option Exercise	0.00	10,208	0	63,838	Jan 17 05:18 PM
Protopapas Anna	Director	Jan 15 '24	Option Exercise	0.00	38,958	0	154,552	Jan 17 05:21 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 15 '24	Option Exercise	0.00	5,352	0	28,353	Jan 17 05:20 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 14 '24	Option Exercise	0.00	4,783	0	23,001	Jan 17 05:20 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 14 '24	Option Exercise	0.00	1,458	0	21,323	Jan 17 05:21 PM
Protopapas Anna	Director	Jan 14 '24	Option Exercise	0.00	16,750	0	115,594	Jan 17 05:21 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 14 '24	Option Exercise	0.00	2,500	0	31,784	Jan 17 05:18 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 14 '24	Option Exercise	0.00	6,250	0	55,630	Jan 17 05:18 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 14 '24	Option Exercise	0.00	4,792	0	194,530	Jan 17 05:19 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 13 '24	Option Exercise	0.00	9,375	0	189,738	Jan 17 05:19 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 13 '24	Option Exercise	0.00	10,000	0	47,380	Jan 17 05:18 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 13 '24	Option Exercise	0.00	8,958	0	29,284	Jan 17 05:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 13 '24	Option Exercise	0.00	8,750	0	17,483	Jan 17 05:16 PM
Protopapas Anna	Director	Jan 13 '24	Option Exercise	0.00	31,250	0	98,844	Jan 17 05:21 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 13 '24	Option Exercise	0.00	7,083	0	19,865	Jan 17 05:21 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 13 '24	Option Exercise	0.00	2,645	0	18,218	Jan 17 05:20 PM
Bala Mohan	SVP, Chief Development Officer	Oct 26 '23	Sale	1.13	1,912	2,161	8,733	Oct 27 04:07 PM
Bala Mohan	SVP, Chief Development Officer	Oct 25 '23	Option Exercise	0.00	6,250	0	10,645	Oct 27 04:07 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Aug 17 '23	Sale	1.18	1,908	2,251	11,507	Aug 18 04:01 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Aug 16 '23	Option Exercise	0.00	6,250	0	13,415	Aug 18 04:01 PM

Open in Screener

NUVL

Nuvalent Inc

Apr 26 • 04:00PM ET

66.86

Dollar change +0.79
Percentage change 1.20	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VBR IWM VXF IBB IWO DWAS SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.16	Insider Own	49.00%	Shs Outstand	58.63M	Perf Week	6.53%
Market Cap	4.28B	Forward P/E	-	EPS next Y	-3.34	Insider Trans	-4.20%	Shs Float	32.67M	Perf Month	-12.76%
Income	-126.22M	PEG	-	EPS next Q	-0.66	Inst Own	61.15%	Short Float	20.98%	Perf Quarter	-12.37%
Sales	0.00M	P/S	-	EPS this Y	-32.59%	Inst Trans	-1.04%	Short Ratio	14.22	Perf Half Y	26.65%
Book/sh	10.94	P/B	6.11	EPS next Y	-16.01%	ROA	-20.78%	Short Interest	6.85M	Perf Year	90.16%
Cash/sh	11.24	P/C	5.95	EPS next 5Y	-	ROE	-21.70%	52W Range	33.03 - 89.39	Perf YTD	-9.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-72.54%	ROI	-18.02%	52W High	-25.20%	Beta	1.36
Dividend TTM	-	Quick Ratio	22.83	Sales past 5Y	0.00%	Gross Margin	-	52W Low	102.42%	ATR (14)	2.92
Dividend Ex-Date	-	Current Ratio	22.83	EPS Y/Y TTM	-31.75%	Oper. Margin	0.00%	RSI (14)	41.75	Volatility	3.64% 4.06%
Employees	92	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.10	Target Price	101.11
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-26.40%	Payout	-	Rel Volume	0.48	Prev Close	66.07
Sales Surprise	-	EPS Surprise	-2.99%	Sales Q/Q	-	Earnings	Feb 27 BMO	Avg Volume	482.01K	Price	66.86
SMA20	-2.11%	SMA50	-13.24%	SMA200	6.17%	Trades		Volume	230,261	Change	1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-24	Initiated	Jefferies	Buy	$97
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform	$69 → $110
Feb-28-24	Resumed	Guggenheim	Buy	$99
Feb-23-24	Initiated	Robert W. Baird	Outperform	$105
Sep-27-23	Initiated	Stifel	Buy	$65
Aug-08-23	Initiated	SVB Securities	Market Perform	$42
Jul-24-23	Initiated	Guggenheim	Buy	$56
Jan-18-23	Initiated	Wedbush	Outperform	$39
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28

Apr-08-24 04:30PM	Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Apr-05-24 07:00PM	Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-29-24 07:01PM	Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-25-24 07:01PM	Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
07:01PM	Loading…
Mar-19-24 07:01PM	Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-05-24 04:52PM	Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Feb-29-24 04:32AM	Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... (GuruFocus.com)
Feb-27-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
06:15AM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 (PR Newswire)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-12-24 06:30AM	Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors (PR Newswire)
Feb-01-24 06:30AM	Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (PR Newswire)
Jan-08-24 06:30AM	Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones (PR Newswire)
Dec-22-23 03:01PM	Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
01:01PM	Loading…
Dec-21-23 01:01PM	Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30AM	Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-14-23 07:15PM	Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com)
06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-04-23 07:02AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Nov-01-23 06:30AM	Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 06:27PM	Why Nuvalent Stock Tanked on Tuesday (Motley Fool) -8.28%
Oct-16-23 09:55PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:30AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-13-23 06:30AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC (PR Newswire)
Oct-07-23 01:00AM	Insider Sell: Chief Medical Officer Christopher Turner Sells 7,995 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-05-23 07:13PM	Why Nuvalent Stock Skyrocketed 35% This Week (Motley Fool) +8.52%
10:29AM	Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data (Zacks)
01:01AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
04:13PM	Loading…
Oct-04-23 04:13PM	Why Nuvalent Stock Was Soaring Wednesday (Motley Fool) +35.57%
12:21PM	Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile (PR Newswire)
Sep-18-23 06:30AM	Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium (PR Newswire) -6.08%
Sep-05-23 06:30AM	Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors (PR Newswire)
Aug-31-23 06:30AM	Nuvalent to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace)
Aug-10-23 06:30AM	Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 06:30AM	Nuvalent to Participate in Upcoming August Investor Conferences (PR Newswire)
Jul-21-23 08:50AM	Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why (Zacks)
Jun-07-23 08:50AM	Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-24-23 06:30AM	Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit (PR Newswire)
May-11-23 06:30AM	Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-19-23 06:30AM	Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days (PR Newswire) +5.13%
Apr-18-23 09:00AM	Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 (PR Newswire)
Apr-02-23 10:56AM	Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Mar-23-23 06:30AM	Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023) (PR Newswire)
Mar-16-23 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire) +5.45%
Mar-14-23 05:59PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023 (PR Newswire) +6.05%
Mar-01-23 06:30AM	Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference (PR Newswire)
Jan-04-23 06:30AM	Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-23 09:40AM	Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year? (Zacks)
Dec-13-22 10:15AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 (PR Newswire)
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Dec-02-22 08:50AM	Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going (Zacks)
Nov-17-22 12:00PM	What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now? (Zacks)
Nov-10-22 06:30AM	Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-03-22 08:13PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire) -6.04%
Oct-31-22 09:14PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:15AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-28-22 04:18PM	Nuvalent stock jumps on positive data from cancer drug trial (American City Business Journals) +60.64%
04:06PM	Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win (Investor's Business Daily)
11:10AM	Why Nuvalent Shares Are Surging 45% Today? (Benzinga)
12:01AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC (PR Newswire)
Oct-26-22 06:30AM	Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655 (PR Newswire)
Oct-23-22 09:26AM	We Think Nuvalent (NASDAQ:NUVL) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Oct-17-22 06:30AM	Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium (PR Newswire) +6.99%
Oct-06-22 06:30AM	Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors (PR Newswire)
Sep-20-22 10:16AM	Nuvalent Has Made a Base Pattern on the Charts (TheStreet.com)
Sep-07-22 06:30AM	Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates (PR Newswire) +17.55%
Sep-01-22 06:30AM	Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference (PR Newswire)
Aug-10-22 06:30AM	Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results (PR Newswire) +12.35%
Aug-05-22 06:30AM	Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting (PR Newswire)
Aug-03-22 06:30AM	Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference (PR Newswire)
Jul-20-22 06:30AM	Nuvalent Announces Leadership Promotions (PR Newswire) -7.92%
Jul-13-22 06:30AM	Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting (PR Newswire) +5.39%
Jul-01-22 10:52AM	Nuvalent Has Begun the Bottoming Process (TheStreet.com)
Jun-21-22 06:30AM	Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers (PR Newswire) +10.18%
Jun-02-22 06:38AM	Nuvalent to Present at the 2022 Jefferies Healthcare Conference (PR Newswire)
May-16-22 09:10AM	Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation (Simply Wall St.) -7.50%
May-12-22 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results (PR Newswire)
Apr-11-22 07:21AM	Nuvalent Highlights New Data Exhibiting Expanded Preclinical Activity Of NVL-520 In ROS1-Driven Cancers (Benzinga) -6.62%
Apr-08-22 01:15PM	Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 (PR Newswire)
Apr-07-22 06:30AM	Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference (PR Newswire)
Mar-31-22 06:30AM	Nuvalent Appoints Anna Protopapas as Chair of Board of Directors (PR Newswire)
Mar-29-22 06:30AM	Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (PR Newswire) +7.49%
Mar-08-22 05:38PM	Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 (PR Newswire)
Mar-02-22 06:30AM	Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference (PR Newswire)
Feb-03-22 06:30AM	Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors (PR Newswire)
Jan-07-22 06:30AM	Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor (PR Newswire)
Jan-04-22 06:30AM	Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-10-21 06:30AM	Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results (PR Newswire)
Oct-29-21 09:55AM	Here's What Nuvalent, Inc.'s (NASDAQ:NUVL) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Oct-07-21 09:21AM	New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC (PR Newswire) -6.53%
Sep-08-21 06:30AM	Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results (PR Newswire)
Aug-06-21 06:26PM	Translate Bio, Nuvalent See Activist Action (Barrons.com) -11.19%
Aug-02-21 05:39PM	Nuvalent Announces Closing of Upsized Initial Public Offering (PR Newswire) +20.05%
Jul-28-21 11:22PM	Nuvalent Announces Pricing of Initial Public Offering (PR Newswire)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shair Matthew	Director	Apr 22 '24	Sale	63.65	37,500	2,386,910	1,537,198	Apr 24 04:44 PM
Conley Emily	Director	Apr 15 '24	Option Exercise	9.36	5,000	46,800	5,008	Apr 17 04:44 PM
Shair Matthew	Director	Apr 15 '24	Sale	65.56	37,500	2,458,335	1,574,698	Apr 17 04:46 PM
Conley Emily	Director	Apr 15 '24	Sale	65.52	5,000	327,607	8	Apr 17 04:44 PM
Shair Matthew	Director	Apr 08 '24	Sale	68.44	37,500	2,566,479	1,612,198	Apr 10 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Apr 04 '24	Option Exercise	6.89	3,000	20,670	36,300	Apr 05 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Apr 04 '24	Sale	73.60	3,000	220,787	33,300	Apr 05 04:47 PM
Shair Matthew	Director	Apr 01 '24	Sale	76.92	37,500	2,884,337	1,649,698	Apr 03 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Mar 28 '24	Option Exercise	22.58	22,000	496,740	55,300	Mar 29 04:46 PM
Miller Deborah Ann	Chief Legal Officer	Mar 28 '24	Sale	75.20	22,000	1,654,311	33,300	Mar 29 04:46 PM
Hack Andrew A. F.	Director	Mar 27 '24	Sale	72.77	880,000	64,035,959	2,697,267	Mar 29 05:15 PM
Shair Matthew	Director	Mar 25 '24	Sale	76.77	37,500	2,878,982	1,687,198	Mar 27 04:55 PM
Shair Matthew	Director	Mar 25 '24	Sale	76.77	2,000	153,546	238,522	Mar 27 04:55 PM
Noci Darlene	Chief Development Officer	Mar 22 '24	Option Exercise	7.74	20,000	154,800	53,300	Mar 25 04:49 PM
Noci Darlene	Chief Development Officer	Mar 22 '24	Sale	77.51	20,000	1,550,229	33,300	Mar 25 04:49 PM
Conley Emily	Director	Mar 15 '24	Option Exercise	9.36	13,333	124,797	13,341	Mar 19 04:46 PM
Conley Emily	Director	Mar 15 '24	Sale	80.92	13,333	1,078,883	8	Mar 19 04:46 PM
Shair Matthew	Director	Dec 28 '23	Sale	75.46	48,548	3,663,492	1,724,698	Dec 28 05:09 PM
Shair Matthew	Director	Dec 27 '23	Sale	75.17	1,000	75,170	1,773,246	Dec 28 05:09 PM
Shair Matthew	Director	Dec 26 '23	Sale	75.12	69,602	5,228,346	1,774,246	Dec 28 05:09 PM
Miller Deborah Ann	Chief Legal Officer	Dec 19 '23	Option Exercise	18.93	5,000	94,650	5,000	Dec 20 04:54 PM
Miller Deborah Ann	Chief Legal Officer	Dec 19 '23	Sale	75.00	5,000	375,000	0	Dec 20 04:54 PM
Miller Deborah Ann	Chief Legal Officer	Dec 18 '23	Option Exercise	27.85	33,046	920,331	33,046	Dec 20 04:54 PM
Noci Darlene	Chief Development Officer	Dec 18 '23	Option Exercise	4.70	40,000	188,139	40,000	Dec 20 04:56 PM
Protopapas Anna	Director	Dec 18 '23	Option Exercise	9.36	5,000	46,800	5,000	Dec 20 04:58 PM
Balcom Alexandra	Chief Financial Officer	Dec 18 '23	Option Exercise	1.08	30,000	32,400	30,000	Dec 20 04:51 PM
Noci Darlene	Chief Development Officer	Dec 18 '23	Sale	75.82	40,000	3,032,800	0	Dec 20 04:56 PM
Miller Deborah Ann	Chief Legal Officer	Dec 18 '23	Sale	75.82	33,046	2,505,548	0	Dec 20 04:54 PM
Balcom Alexandra	Chief Financial Officer	Dec 18 '23	Sale	75.82	30,000	2,274,600	0	Dec 20 04:51 PM
Protopapas Anna	Director	Dec 18 '23	Sale	75.67	5,000	378,350	0	Dec 20 04:58 PM
Shair Matthew	Director	Nov 28 '23	Sale	61.89	9,150	566,303	1,843,848	Nov 30 04:47 PM
Noci Darlene	Chief Development Officer	Nov 01 '23	Option Exercise	1.08	3,000	3,240	3,000	Nov 03 04:43 PM
Noci Darlene	Chief Development Officer	Nov 01 '23	Sale	52.66	3,000	157,975	0	Nov 03 04:43 PM
Shair Matthew	Director	Oct 24 '23	Sale	50.70	91,700	4,648,872	1,852,998	Oct 26 04:47 PM
Noci Darlene	Chief Development Officer	Oct 04 '23	Option Exercise	5.56	20,000	111,150	20,000	Oct 06 04:56 PM
Turner Christopher Durant	Chief Medical Officer	Oct 04 '23	Option Exercise	6.89	7,995	55,086	22,508	Oct 06 04:58 PM
Noci Darlene	Chief Development Officer	Oct 04 '23	Sale	55.99	20,000	1,119,702	0	Oct 06 04:56 PM
Turner Christopher Durant	Chief Medical Officer	Oct 04 '23	Sale	54.04	7,995	432,031	14,513	Oct 06 04:58 PM
Noci Darlene	Chief Development Officer	Oct 02 '23	Option Exercise	1.08	3,000	3,240	3,000	Oct 04 04:24 PM
Noci Darlene	Chief Development Officer	Oct 02 '23	Sale	45.88	3,000	137,649	0	Oct 04 04:24 PM
Miller Deborah Ann	Chief Legal Officer	Sep 15 '23	Option Exercise	6.89	2,000	13,780	2,000	Sep 19 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Sep 15 '23	Sale	47.64	2,000	95,283	0	Sep 19 04:45 PM
Noci Darlene	Chief Development Officer	Sep 01 '23	Option Exercise	1.08	3,000	3,240	3,000	Sep 06 04:36 PM
Noci Darlene	Chief Development Officer	Sep 01 '23	Sale	46.56	3,000	139,692	0	Sep 06 04:36 PM
Miller Deborah Ann	Chief Legal Officer	Aug 15 '23	Option Exercise	6.89	2,000	13,780	2,000	Aug 17 04:29 PM
Miller Deborah Ann	Chief Legal Officer	Aug 15 '23	Sale	42.65	2,000	85,310	0	Aug 17 04:29 PM
Noci Darlene	Chief Development Officer	Aug 01 '23	Option Exercise	1.08	3,000	3,240	3,000	Aug 01 05:26 PM
Noci Darlene	Chief Development Officer	Aug 01 '23	Sale	49.95	3,000	149,844	0	Aug 01 05:26 PM
Balcom Alexandra	Chief Financial Officer	Jul 31 '23	Option Exercise	1.08	25,000	27,000	25,000	Aug 01 04:16 PM
Balcom Alexandra	Chief Financial Officer	Jul 31 '23	Sale	48.99	25,000	1,224,796	0	Aug 01 04:16 PM
Miller Deborah Ann	Chief Legal Officer	Jul 28 '23	Option Exercise	6.89	6,500	44,785	6,500	Aug 01 04:13 PM
Turner Christopher Durant	Chief Medical Officer	Jul 28 '23	Option Exercise	6.89	2,665	18,362	17,178	Jul 28 04:51 PM
Miller Deborah Ann	Chief Legal Officer	Jul 28 '23	Sale	48.52	6,500	315,380	0	Aug 01 04:13 PM
Turner Christopher Durant	Chief Medical Officer	Jul 28 '23	Sale	48.93	2,665	130,398	14,513	Jul 28 04:51 PM
Turner Christopher Durant	Chief Medical Officer	Jul 26 '23	Option Exercise	6.89	2,365	16,295	16,878	Jul 28 04:51 PM
Turner Christopher Durant	Chief Medical Officer	Jul 26 '23	Sale	46.85	2,365	110,800	14,513	Jul 28 04:51 PM
Turner Christopher Durant	Chief Medical Officer	Jul 24 '23	Option Exercise	6.89	200	1,378	14,713	Jul 24 04:54 PM
Turner Christopher Durant	Chief Medical Officer	Jul 24 '23	Sale	46.82	200	9,364	14,513	Jul 24 04:54 PM
Noci Darlene	Chief Development Officer	Jul 20 '23	Option Exercise	1.08	10,941	11,816	10,941	Jul 21 04:47 PM
Turner Christopher Durant	Chief Medical Officer	Jul 20 '23	Option Exercise	6.89	100	689	14,613	Jul 24 04:54 PM
Noci Darlene	Chief Development Officer	Jul 20 '23	Sale	45.17	10,941	494,205	0	Jul 21 04:47 PM
Turner Christopher Durant	Chief Medical Officer	Jul 20 '23	Sale	46.80	100	4,680	14,513	Jul 24 04:54 PM
Noci Darlene	Chief Development Officer	Jul 19 '23	Option Exercise	1.08	4,559	4,924	4,559	Jul 21 04:47 PM
Noci Darlene	Chief Development Officer	Jul 19 '23	Sale	45.04	4,559	205,337	0	Jul 21 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Jul 17 '23	Option Exercise	6.89	2,000	13,780	2,000	Jul 19 04:43 PM
Miller Deborah Ann	Chief Legal Officer	Jul 17 '23	Sale	43.06	2,000	86,123	0	Jul 19 04:43 PM
Noci Darlene	Chief Development Officer	Jul 03 '23	Option Exercise	1.08	3,000	3,240	3,000	Jul 06 04:51 PM
Noci Darlene	Chief Development Officer	Jul 03 '23	Sale	41.48	3,000	124,427	0	Jul 06 04:51 PM
Noci Darlene	Chief Development Officer	Jun 16 '23	Option Exercise	1.08	2,900	3,132	2,900	Jun 20 04:45 PM
Noci Darlene	Chief Development Officer	Jun 16 '23	Sale	45.19	2,900	131,051	0	Jun 20 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jun 15 '23	Option Exercise	6.89	2,000	13,780	2,000	Jun 20 04:42 PM
Noci Darlene	Chief Development Officer	Jun 15 '23	Option Exercise	1.08	1,000	1,080	1,000	Jun 20 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jun 15 '23	Sale	44.28	2,000	88,565	0	Jun 20 04:42 PM
Noci Darlene	Chief Development Officer	Jun 15 '23	Sale	45.07	1,000	45,070	0	Jun 20 04:45 PM
Turner Christopher Durant	Chief Medical Officer	Jun 05 '23	Option Exercise	6.89	10,235	70,519	24,748	Jun 07 04:50 PM
Noci Darlene	Chief Development Officer	Jun 05 '23	Option Exercise	1.08	600	648	600	Jun 07 04:46 PM
Turner Christopher Durant	Chief Medical Officer	Jun 05 '23	Sale	44.86	10,235	459,142	14,513	Jun 07 04:50 PM
Noci Darlene	Chief Development Officer	Jun 05 '23	Sale	45.00	600	27,000	0	Jun 07 04:46 PM
Noci Darlene	Chief Development Officer	Jun 01 '23	Option Exercise	1.08	3,000	3,240	3,000	Jun 02 04:45 PM
Noci Darlene	Chief Development Officer	Jun 01 '23	Sale	42.64	3,000	127,921	0	Jun 02 04:45 PM
Miller Deborah Ann	Chief Legal Officer	May 15 '23	Option Exercise	6.89	2,000	13,780	2,000	May 17 04:44 PM
Miller Deborah Ann	Chief Legal Officer	May 15 '23	Sale	40.74	2,000	81,489	0	May 17 04:44 PM
Miller Deborah Ann	Chief Legal Officer	May 09 '23	Option Exercise	6.89	1,332	9,177	1,332	May 09 05:11 PM
Miller Deborah Ann	Chief Legal Officer	May 09 '23	Sale	39.63	1,332	52,787	0	May 09 05:11 PM
Miller Deborah Ann	Chief Legal Officer	May 05 '23	Option Exercise	6.89	2,800	19,292	2,800	May 09 05:11 PM
Miller Deborah Ann	Chief Legal Officer	May 05 '23	Sale	39.64	2,800	110,992	0	May 09 05:11 PM
Miller Deborah Ann	Chief Legal Officer	May 01 '23	Option Exercise	6.89	900	6,201	900	May 03 04:38 PM
Noci Darlene	Chief Development Officer	May 01 '23	Option Exercise	1.08	3,000	3,240	3,000	May 03 04:41 PM
Noci Darlene	Chief Development Officer	May 01 '23	Sale	38.60	3,000	115,787	0	May 03 04:41 PM
Miller Deborah Ann	Chief Legal Officer	May 01 '23	Sale	39.61	900	35,649	0	May 03 04:38 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

MRSN

Mersana Therapeutics Inc

NUVL

Nuvalent Inc

Upgrade your FINVIZ experience